Brokerages expect Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) to report earnings of $1.83 per share for the current fiscal quarter, Zacks reports. Eight analysts have provided estimates for Alexion Pharmaceuticals’ earnings. The highest EPS estimate is $1.99 and the lowest is $1.71. Alexion Pharmaceuticals posted earnings of $1.48 per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 23.6%. The firm is scheduled to report its next earnings results on Thursday, February 14th.
According to Zacks, analysts expect that Alexion Pharmaceuticals will report full-year earnings of $7.57 per share for the current year, with EPS estimates ranging from $7.17 to $7.77. For the next fiscal year, analysts forecast that the company will post earnings of $8.70 per share, with EPS estimates ranging from $7.86 to $9.39. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that cover Alexion Pharmaceuticals.
Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its earnings results on Wednesday, October 24th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating the consensus estimate of $1.74 by $0.28. The firm had revenue of $1.03 billion during the quarter, compared to analyst estimates of $1.02 billion. Alexion Pharmaceuticals had a net margin of 3.90% and a return on equity of 16.60%. The business’s quarterly revenue was up 19.5% on a year-over-year basis. During the same period in the previous year, the firm earned $1.44 EPS.
Institutional investors and hedge funds have recently made changes to their positions in the business. First Hawaiian Bank acquired a new stake in Alexion Pharmaceuticals during the 3rd quarter worth $102,000. Advisory Services Network LLC boosted its stake in Alexion Pharmaceuticals by 145.3% during the 2nd quarter. Advisory Services Network LLC now owns 883 shares of the biopharmaceutical company’s stock worth $121,000 after purchasing an additional 523 shares during the last quarter. Columbia Asset Management acquired a new stake in Alexion Pharmaceuticals during the 3rd quarter worth $138,000. Checchi Capital Advisers LLC acquired a new stake in Alexion Pharmaceuticals during the 3rd quarter worth $204,000. Finally, Integrated Wealth Concepts LLC acquired a new stake in Alexion Pharmaceuticals during the 3rd quarter worth $205,000. 93.64% of the stock is currently owned by institutional investors.
Shares of NASDAQ:ALXN traded up $3.57 during trading on Thursday, hitting $119.68. 991,140 shares of the stock traded hands, compared to its average volume of 1,756,633. The company has a debt-to-equity ratio of 0.32, a current ratio of 3.16 and a quick ratio of 2.74. The firm has a market cap of $26.46 billion, a price-to-earnings ratio of 23.19, a price-to-earnings-growth ratio of 1.02 and a beta of 0.99. Alexion Pharmaceuticals has a 52-week low of $102.10 and a 52-week high of $140.77.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease.
Read More: Asset Allocation, Balancing Your Investments
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.